Luminal B型乳腺癌的临床病理特征及预后分析

Clinical pathological features and prognosis of Luminal type B breast cancer

目的探讨Luminal B型乳腺癌两种亚型的临床病理特征及预后的差异。方法回顾性分析经免疫组织化学分型确定的129例Luminal B-HER-2(-)型和49例Luminal B-HER-2(+)型乳腺癌患者,比较其临床病理特征及治疗方式对预后的影响。结果与Luminal B-HER-2(-)型比较,Luminal B-HER-2(+)型乳腺癌患者腋窝淋巴结转移率较高(P=0.017),Ki-67表达较高(P=0.046)。Luminal B-HER-2(+)型乳腺癌患者放疗比例较高(P=0.012)。中位随访时间26个月,Luminal B-HER-2(-)型与Luminal B-HER-2(+)型乳腺癌患者的无病生存率分别为91.7%和77.2%(P=0.032)。结论与Luminal B-HER-2(-)型比较,Luminal B-HER-2(+)型乳腺癌具有较差的临床病理学特征,预后较差。

Objective To investigate the clinical pathological features and prognosis of two breast cancer subtype of Luminal type B. Methods Determined 129 cases Luminal B-HER-2（-）type and 49 cases Luminal B-HER-2（＋）type in patients with breast cancer by retrospective analysis of immunohistochemistry method,compared the effect of the clinical pathologic features and therapy method on the prognosis. Results Compared with Luminal B-HER-2（-）type,Luminal B-HER-2（＋） type breast cancer patients had higher axillary lymph node metastasis rate（P=0.017）,higher Ki-67 expression（P=0.046）. Luminal B-HER-2（＋） breast cancer patients had higher proportion of radiotherapy（P=0.012）. Median follow-up time was 26 months,the disease-free survival rate of Luminal B-HER-2（-） and Luminal B-HER-2（＋） breast cancer patients was respectively 91.7% and 77.2%（P=0.032）. ConclusionCompared with Luminal B-HER-2（-）type,Luminal B-HER-2（＋）type breast cancer has poorer clinical pathological features and prognosis.